{
    "organizations": [],
    "uuid": "90421694bc7ab4c22bfc74f5dc658c07810359a5",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-rxi-pharmaceuticals-announces-busi/brief-rxi-pharmaceuticals-announces-business-strategy-to-focus-on-immuno-oncology-programs-to-accelerate-growth-idUSFWN1PB0LU",
    "ord_in_thread": 0,
    "title": "BRIEF-RXi Pharmaceuticals Announces Business Strategy To Focus On Immuno-Oncology Programs To Accelerate Growth",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 16 (Reuters) - Rxi Pharmaceuticals Corp:\n* RXI PHARMACEUTICALS ANNOUNCES BUSINESS STRATEGY TO FOCUS ON IMMUNO-ONCOLOGY PROGRAMS TO ACCELERATE GROWTH\n* RXI PHARMACEUTICALS CORP - COMPANY TO “CAPITALIZE” ON PROPRIETARY SELF-DELIVERING RNAI PLATFORM (SD-RXRNA)\n* RXI PHARMACEUTICALS CORP - 2018 BUSINESS STRATEGY INCLUDES DEVELOPING IMMUNO-ONCOLOGY TARGETS BEYOND CHECKPOINT INHIBITION, I.E. CELL DIFFERENTIATION\n* RXI PHARMACEUTICALS- RELATING TO OPERATIONAL REVIEW, RXI INTENDS TO PARTNER/OUT-LICENSE BOTH ITS DERMATOLOGY AND OPHTHALMOLOGY FRANCHISES Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-16T20:35:00.000+02:00",
    "crawled": "2018-01-17T19:48:46.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "rxi",
        "pharmaceutical",
        "corp",
        "rxi",
        "pharmaceutical",
        "announces",
        "business",
        "strategy",
        "focus",
        "program",
        "accelerate",
        "growth",
        "rxi",
        "pharmaceutical",
        "corp",
        "company",
        "capitalize",
        "proprietary",
        "rnai",
        "platform",
        "rxi",
        "pharmaceutical",
        "corp",
        "business",
        "strategy",
        "includes",
        "developing",
        "target",
        "beyond",
        "checkpoint",
        "inhibition",
        "cell",
        "differentiation",
        "rxi",
        "relating",
        "operational",
        "review",
        "rxi",
        "intends",
        "dermatology",
        "ophthalmology",
        "franchise",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}